By Annalee Armstrong
BioNTech’s post-Comirnaty future is emerging, with early phase 1/2 data from a solid tumor CAR-T cell therapy showing evidence of efficacy and a safety profile deemed manageable by the famed German biotech.
read more
By Angus Liu
Bristol Myers Squibb presented details on what triggered a quick FDA nod in March for Opdivo in early-stage non-small cell lung cancer before surgery, including a disease worsening benefit across patient groups and an early sign of life extension.
read more
By Angus Liu
Amgen is busy building Lumakras’ case, taking advantage of an unexpectedly longer lead over KRAS rival Mirati Therapeutics. Two years in, Lumakras’ data in previously treated KRAS G12C-mutated non-small cell lung cancer continued to look solid.
read more
By Angus Liu
Senti Bio is perhaps best known for logic-gated gene circuits to control the therapeutic activity of cell and gene therapies. But CEO Tim Lu, M.D., Ph.D., has early data showing the biotech's CAR-NK platform has more tricks up its sleeve.
read more
By Angus Liu
Existing CAR-T therapies for blood cancers require painstaking preparation. Exuma Biotech believes its rapidly manufactured cell therapy can save patients precious time and obviate the need for preconditioning.
read more
By Angus Liu
When Novartis failed in an attempt to repurpose Ilaris for metastatic non-small cell lung cancer, the Swiss pharma played up signs that it said supported continued exploration of the med in earlier stages of disease. Now, the company has unveiled those data.
read more
By Annalee Armstrong
C4 Therapeutics has learned a lot from just five melanoma patients reporting out from the first cohort in a phase 1 trial for its lead candidate, a IKZF1/3 degrader called CFT7455. In data to be presented at the AACR meeting in New Orleans on April 12, C4 will showcase the early efficacy signals.
read more
By Annalee Armstrong
About seven out of 10 patients with EGFR-mutated lung cancer progress after taking AstraZeneca’s Tagrisso, and a third of those patients see their cancer spread to the brain. Blueprint wants to change that.
read more
By Annalee Armstrong
Myelofibrosis is the cancer that keeps going and going—and AbbVie hopes new data from the phase 2 med navitoclax can make the case for stopping the rare and difficult-to-treat disease in its tracks.
read more
